Cardiac fibrosis
Open accessThe DOI matches its Crossref record; 612 of the 615 references it cites were found in a registry or an index.
Abstract
Myocardial fibrosis, the expansion of the cardiac interstitium through deposition of extracellular matrix proteins, is a common pathophysiologic companion of many different myocardial conditions. Fibrosis may reflect activation of reparative or maladaptive processes. Activated fibroblasts and myofibroblasts are the central cellular effectors in cardiac fibrosis, serving as the main source of matrix proteins. Immune cells, vascular cells and cardiomyocytes may also acquire a fibrogenic phenotype under conditions of stress, activating fibroblast populations. Fibrogenic growth factors (such as transforming growth factor-β and platelet-derived growth factors), cytokines [including tumour necrosis factor-α, interleukin (IL)-1, IL-6, IL-10, and IL-4], and neurohumoral pathways trigger fibrogenic signalling cascades through binding to surface receptors, and activation of downstream signalling cascades. In addition, matricellular macromolecules are deposited in the remodelling myocardium and regulate matrix assembly, while modulating signal transduction cascades and protease or growth factor activity. Cardiac fibroblasts can also sense mechanical stress through mechanosensitive receptors, ion channels and integrins, activating intracellular fibrogenic cascades that contribute to fibrosis in response to pressure overload. Although subpopulations of fibroblast-like cells may exert important protective actions in both reparative and interstitial/perivascular fibrosis, ultimately fibrotic changes perturb systolic and diastolic function, and may play an important role in the pathogenesis of arrhythmias. This review article discusses the molecular mechanisms involved in the pathogenesis of cardiac fibrosis in various myocardial diseases, including myocardial infarction, heart failure with reduced or preserved ejection fraction, genetic cardiomyopathies, and diabetic heart disease. Development of fibrosis-targeting therapies for patients with myocardial diseases will require not only understanding of the functional pluralism of cardiac fibroblasts and dissection of the molecular basis for fibrotic remodelling, but also appreciation of the pathophysiologic heterogeneity of fibrosis-associated myocardial disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inflammation and tissue fibrosis co-exist and are causally linked to organ dysfunction1,2.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [2]
In the citing paper
“Among stromal cell types, fibroblasts are of particular interest given their role in tissue fibrosis, arrhythmias, and heart failure 16,29,30 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [30]
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495 · cited 1×
“Fibrosis is an important cause of organ dysfunction in many different diseases, including interstitial lung diseases, liver cirrhosis, progressive systemic sclerosis, and diabetic nephropathy.(1)”
BackgroundMyofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Obesity and the risk of heart failure
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, M. G., Kannel, W. B., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020245 · Cited by 3,093
Ignotz, R. A., & Massagué, J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35666-1 · Cited by 2,492
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis
Prabhu, S. D., & Frangogiannis, N. G. (2016) · Circulation Research · doi:10.1161/circresaha.116.303577 · Cited by 2,224
Self-citationEndothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222 · cited 2×
“The antifibrotic effects were attributed to blockade of TGF-b signalling and were associated with attenuated endothelial to mesenchymal transition.(22,247) Moreover, gain-of-function studies have”
BackgroundHinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Cited by
Items 501–600 of 1,000
Zhou, J., Chen, Y., Chen, J., Xia, G., Zeng, J., & Wang, L. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-025-10081-z · Cited by 10
Siqueira, S., Pabón, M. A., Vaduganathan, M., Claggett, B. L., Lam, C. S. P., Kosiborod, M., de Boer, R. A., Shah, S. J., Fang, J. C.-T., Desai, A. S., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102585 · Cited by 9
Redox-architected signaling networks in cardiac fibrosis
Zhang, Y., Zhong, Y., Zeng, Q., & Tang, M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152553 · Cited by 9
CAR-T cells generated in vivo for the targeted treatment of myocardial fibrosis
Xu, L., Du, Z., Zhang, Y., Lv, X., Zhang, C., & Li, D. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115840 · Cited by 10
Astragaloside IV: A multipotent phytochemical for treating fibrotic diseases (Review)
Wu, M., Li, K., Wu, J., Zhang, Q., Ma, X., Dai, W., Gao, H., Ding, X., Wang, W., & Xiao, W. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5721 · Cited by 10
Leveraging Single-Cell Technologies to Advance Understanding of Myocardial Disease
Gardner, R. S., Tucker, N. R., & Amancherla, K. V. (2026) · Circulation Research · doi:10.1161/circresaha.125.326002 · Cited by 10
Liquid–Liquid Phase Separation Sheds New Light upon Cardiovascular Diseases
Cai, Z., Mei, S., Li, Z., Ma, X., Wuyun, Q., Yan, J., & Ding, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015418 · Cited by 10
Telesca, M., Donniacuo, M., Bellocchio, G., Riemma, M. A., Mele, E., Dell’Aversana, C., Sgueglia, G., Cianflone, E., Cappetta, D., Torella, D., et al. (2023) · Cancers · doi:10.3390/cancers16010053 · Cited by 9
Tsuji, Y., Ogata, T., Mochizuki, K., Tamura, S., Morishita, Y., Takamatsu, T., Matoba, S., & Tanaka, H. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1352911 · Cited by 9
Ogilvie, L. M., Coyle‐Asbil, B., Brunt, K. R., Petrik, J., & Simpson, J. A. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00795.2023 · Cited by 9
Andrup, S., Andersen, G. Ø., Hoffmann, P., Eritsland, J., Seljeflot, I., Halvorsen, S., & Vistnes, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302732 · Cited by 9
Patil, M., Singh, S., Dubey, P. K., Tousif, S., Umbarkar, P., Zhang, Q., Lal, H., Sewell-Loftin, M. K., Umeshappa, C. S., Ghebre, Y. T., et al. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.03.004 · Cited by 9
Understanding the roles of salt-inducible kinases in cardiometabolic disease
Shi, F. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1426244 · Cited by 12
“In pathological cardiac remodeling, myocardial fi brosis occurs as deposition of ECM proteins by activated fi broblast, which results in the expansion of cardiac interstitium and ultimately leads to systolic and diastolic dysfunction (Frangogiannis, 2021).”
BackgroundA New Ex Vivo Model to Study Cardiac Fibrosis in Whole Mouse Hearts
Kruithof, B. P. T., Gourabi, B. M., van de Merbel, A. F., DeRuiter, M. C., & Goumans, M. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.04.007 · Cited by 9
Geng, X., Shang, W.-Y., Qi, Z., Zhang, C., Li, W.-X., Yan, Z., Fan, X., & Zhang, J. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108848 · Cited by 9
Advances in the pharmacological mechanisms of berberine in the treatment of fibrosis
Liu, X., Liang, Q., Wang, Y., Xiong, S., & Yue, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1455058 · Cited by 14
“Activated CFs are central cellular effectors of MF and are the main source of ECM proteins in MF (Frangogiannis, 2021).”
BackgroundYuan, Z., Huang, S., Jin, X. K., & Li, S. (2024) · Genes · doi:10.3390/genes15111423 · Cited by 10
Ali, S. A., Perera, G., Laird, J., Batorsky, R., Maron, M. S., Rivas, V. N., Stern, J. A., Harris, S. P., & Chin, M. T. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035780 · Cited by 9
“34 Cardiac fibroblasts are thought to be the primary drivers of ECM production, 35 although other cells can contribute.”
The m7G methylation modification: An emerging player of cardiovascular diseases
Xu, C., Yu, X.-H., Wang, G., Luo, W., Chen, L., & Xia, X.-D. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142940 · Cited by 9
Cardiotonic Pills® protects from myocardial fibrosis caused by in stent restenosis in miniature pigs
Yan, L., Wei, X., Shi, Q.-P., Pan, C., Li, K., Zhang, B., Wang, X., Zheng, B., Wang, M., Li, Y., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154405 · Cited by 9
Kong, Q., Zhou, J., Ma, C., Wei, Z., Chen, Y., Cheng, Y., Wu, W.-C., Zhou, Z., Tang, Y., & Liu, X. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106677 · Cited by 9
Shen, C., Fang, R., Wang, J., Wu, N., Wang, S., Shu, T., Dai, J., Feng, M., & Chen, X. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17854 · Cited by 10
Effects of Dapagliflozin on Myocardial Gene Expression in BTBR Mice with Type 2 Diabetes
Ryaboshapkina, M., Ye, R., Ye, Y., & Birnbaum, Y. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07517-1 · Cited by 9
“Smad3 is involved in cardiac fibrosis [105].”
m6A Ribonucleic Acid Methylation in Fibrotic Diseases of Visceral Organs
Dai, X., Cheng, Y., Luo, W. F., Wang, J., Wang, C., Zhang, X., Zhang, W., & Chao, J. (2024) · Small Science · doi:10.1002/smsc.202400308 · Cited by 8
Nagalingam, R. S., Jayousi, F., Hamledari, H., Baygi, D. H., Dababneh, S., Lindsay, C., Geltink, R. I. K., Lange, P. F., Dixon, I., Rose, R. A., et al. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1496884 · Cited by 8
“To understand the passage-mediated proteome pro fi le changes, we performed PCA to see the clustering differences between non-passaged fi broblasts (P0), myo fi broblasts (P3), and growth factor activated fi broblasts (P0+TGF β 1) using the Benjamini – Hochberg method (Figure 4A).”
InfluentialThe Role of the Extracellular Matrix in Inducing Cardiac Cell Regeneration and Differentiation
Romano, N. (2025) · Cells · doi:10.3390/cells14120875 · Cited by 8
“Disease-specific pathophysiological perturbations may trigger distinct molecular patterns of fibroblast activation that modulate the composition of the interstitial ECM and the administration/diffusion of growth factors [129–131].”
Hu, Y., Huang, Y., Guo, J., Liu, X., & Liu, Y. (2025) · APOPTOSIS · doi:10.1007/s10495-025-02151-8 · Cited by 8
“MF is a pathophysiological condition that accompanies various CVDs involving the formation of scar tissue in the dam - aged heart as a response to inflammatory injury or abnormal wound healing [105].”
Curcumin and its novel formulations for diabetes mellitus and its complications: a review
Liu, X., Liang, Q., Jiang, W., Zhou, J. J., Liu, C., Deng, L., Feng, H., & Yue, R. (2025) · Food & Function · doi:10.1039/d5fo00988j · Cited by 8
Sirtuins as Endogenous Regulators of Cardiac Fibrosis: A Current Perspective
Farhadi, Z., Esmailidehaj, M., Masoumi, S., & Azizian, H. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-10052-0 · Cited by 8
Hosseini, A., Haj‐Yehia, E., Korste, S., Kuzay, Y., Trajkovic-Arsic, M., Settelmeier, S., Cantore, M., Ferenz, K. B., Siveke, J. T., Herrmann, K., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268860 · Cited by 9
ANTXR1 blockade enhances cardiac function in preclinical models of heart failure
Boccella, N., Yu, G., Seaman, S., Feng, Y., Lee, J., Tomassoni‐Ardori, F., Yang, L., Hsu, K.-S., Dunleavey, J. M., Becker, J., et al. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00725-y · Cited by 8
The critical role of LRG1 in pathological fibrosis
Yang, T., & Xu, H. (2025) · Journal of Molecular Medicine · doi:10.1007/s00109-025-02596-z · Cited by 10
“Other contributing factors include PDGF [115, 122] and reactive oxygen species (ROS) [115, 123].”
Emerging insights of fibrinogen glycation in cardiovascular disorders: A review
Ameera, K., Choraria, G., Basha, S., & Mahato, K. K. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148461 · Cited by 9
Han, W., Wang, Z., Guo, H., Wang, M., Cao, L. H., & Sun, G. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157615 · Cited by 8
Ferroptosis in Myocardial Fibrosis: Mechanisms and Therapeutic Insights
Lin, X., Li, W., Ye, J., & Li, L. (2026) · Antioxidants · doi:10.3390/antiox15010070 · Cited by 9
“It is characterized by reduced cardiac function, stiffening of the heart muscles, and even heart failure [1,2].”
Li, Y., Rimon, R. A., Wang, F., Li, H., Epelman, S., Tallquist, M. D., Westover, L., Oudit, G. Y., & Kassiri, Z. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf256 · Cited by 8
The Translation and Commercialisation of Biomarkers for Cardiovascular Disease—A Review
Saleh, S., George, J., Kott, K. A., Meikle, P. J., & Figtree, G. A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.897106 · Cited by 9
“Biomarkers of Fibrosis and Post-infarct Remodeling The heart’s response to ischaemic insult through fibrosis and subsequent remodeling is a principal determinant of it’s longterm function (54).”
BackgroundBack to the basics: The need for an etiological classification of chronic heart failure
Triposkiadis, F. K., Xanthopoulos, A. V., Drakos, S. G., Boudoulas, K. D., Briasoulis, Α., Skoularigis, J. S., Tsioufis, K. P., Boudoulas, H. K., & Starling, R. C. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102460 · Cited by 9
Lee, W. S., Enomoto, T., Akimoto, A. M., & Yoshida, R. (2024) · Chemistry of Materials · doi:10.1021/acs.chemmater.3c02969 · Cited by 8
Current experimental and early investigational agents for cardiac fibrosis: where are we at?
Ciampi, C. M., Sultana, A., Ossola, P., Farina, A., Fragasso, G., & Spoladore, R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2326024 · Cited by 8
“Its pro-fibrotic effect operates through the ALK/Smad2/3/Smad4 signaling pathway, as well as the TAK/p-38/JNK and NOX4/ROS pathways [104,105].”
BackgroundChen, L. L., Hongyu, S., Tao, Z., Liang, C., Zhongzhao, L., Dong, Y., Zheng, P., & Liu, Y. (2024) · Cardiovascular Therapeutics · doi:10.1155/2024/5583961 · Cited by 8
Inducible Fgf13 ablation alleviates cardiac fibrosis via regulation of microtubule stability
Wang, C., Wang, X., Zhang, Y., Mi, Y., Han, Y., Zhi, Y., Zhao, R., Cui, N., Ma, Q., Zhang, H., et al. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024075 · Cited by 10
“The RhoA / ROCK pathway, a mechanosensitive signaling pathway in cardiac fibrosis [6], is regulated by microtubules [17].”
High sugar diet–induced fatty acid oxidation potentiates cytokine-dependent cardiac ECM remodeling
Gera, J., Kumar, D., Chauhan, G., Choudhary, A., Rani, L., Mandal, L., & Mandal, S. (2024) · The Journal of Cell Biology · doi:10.1083/jcb.202306087 · Cited by 8
“…reactive oxygen species (ROS), neurohumoral signals, inflammatory cytokines, growth factors, and adipokines have been implicated in the activation of the resident cardiac fibroblasts for the excessive synthesis of cardiac ECM proteins (Russo and Frangogiannis, 2016; Tuleta and Frangogiannis, 2021).”
Yu, Y.-X., Xu, Y., Chen, J., Yao, Y., Liu, Y., Chen, Y., Yang, B., & Guo, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117254 · Cited by 8
Běhounek, M., Lipcseyová, D., Vít, O., Žáček, P., Talacko, P., Husková, Z., Kikerlová, S., Tykvartová, T., Wohlfahrt, P., Melenovský, V., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011984 · Cited by 8
Zhang, J., Lei, Y., Li, R., He, Y., & Chen, Z. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10678-z · Cited by 8
“Cardiac fibrosis is characterized by excessive extracellular matrix accumulation in the heart muscle, leading to structural and functional alterations primarily through the differentiation of fibroblasts into myofibroblasts [1].”
Micu, M. A., Cozac, D. A., & Scridon, A. (2025) · Diagnostics · doi:10.3390/diagnostics15182286 · Cited by 8
Zhang, J., Cheng, Y., Luo, C., & Yu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.940365 · Cited by 8
“Cardiac fibrosis, as a scarring event in the cardiac muscle, is characterized by net accumulation of extracellular matrix in the myocardium, mediated by cardiac fibroblast (CF) activation and differentiation into myofibroblasts (Yang et al., 2020; Frangogiannis, 2021).”
BackgroundGβγ subunits colocalize with RNA polymerase II and regulate transcription in cardiac fibroblasts
Khan, S. M., Martin, R., Bayne, A. N., Pétrin, D., Bourque, K., Jones-Tabah, J., Bouazza, C. A., Blaney, J., Lau, J., Martins-Cannavino, K., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.103064 · Cited by 10
Identification of circRNA-miRNA-mRNA regulatory network and its role in cardiac hypertrophy
Gong, K. Q., Yang, K., Xie, T., Luo, Y., Guo, H., Tan, Z., Chen, J., Wu, Q., Gong, Y., Wei, L., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0279638 · Cited by 9
“Platelet-derived growth factor binding is intimately associated with cardiomyocyte fibrosis and is also one of the mechanisms underlying HCM [43].”
BackgroundReinal, I., Ontoria‐Oviedo, I., Selva, M., Casini, M., Peiró-Molina, E., Santos, C. F., Climent, A. M., Balaguer, J., Cañete, A., Mora, J., et al. (2023) · Antioxidants · doi:10.3390/antiox12071378 · Cited by 11
“Ventricular cardiomyocytes are capable of activating inflammatory and fibrogenic programs in response to stress [35].”
BackgroundInfluentialThe Role of METTL3 in the Progression of Cardiac Fibrosis
Bolívar, S., Pérez-Cantillo, M., Monterroza-Torres, J., Vásquez-Trincado, C., Castellar-López, J., & Mendoza‐Torres, E. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230825144949 · Cited by 8
Lin, L.-C., Liu, Z., Tu, B., Song, K., Sun, H., Zhou, Y., Sha, J.-M., Ye, Z., Yang, J., Zhao, J., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127593 · Cited by 8
Zhao, J., Yue, P., Mi, N., Li, M., Fu, W., Zhang, X., Gao, L., Bai, M., Tian, L., Jiang, N., et al. (2024) · Medical Review · doi:10.1515/mr-2024-0029 · Cited by 11
Zhu, L., Wang, W., Ren, C., Wang, Y., Zhang, G., Liu, J., & Wang, W. (2022) · Biomedicines · doi:10.3390/biomedicines10020402 · Cited by 11
“Reduced contractility of CMs and myocardial fibrosis are considered to be the main causes of HF, mainly due to a decrease in the number of normal CMs and abnormal extracellular matrix construction [25].”
BackgroundWhole-Exome Sequencing Revealed New Candidate Genes for Human Dilated Cardiomyopathy
D’Agostino, Y., Palumbo, D., Rusciano, M. R., Strianese, O., Amabile, S., Rosa, D. D., Angelis, E. D., Visco, V., Russo, F., Alexandrova, E., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12102411 · Cited by 8
Martins, A. F., Neto, A. C., Rodrigues, A. R., Oliveira, S. M., Sousa-Mendes, C., Leite-Moreira, A. F., Gouveia, A., Almeida, H., & Neves, D. (2022) · Biomedicines · doi:10.3390/biomedicines10112782 · Cited by 10
Tumor Growth Ameliorates Cardiac Dysfunction
Awwad, L., Shofti, R., Haas, T., & Aronheim, A. (2023) · Cells · doi:10.3390/cells12141853 · Cited by 8
“pathophysiologic principles of fibrosis are found in several fibrotic diseases, involving multiple organs such as the liver [36], heart [37,38], skeletal muscles [39], kidney [35] and lungs [40].”
BackgroundMechanisms of Ischemic Heart Injury
Re, D. P. D. (2022) · Cells · doi:10.3390/cells11091384 · Cited by 8
“This includes a highly orchestrated inflammatory response involving cardiomyocytes, cardiac fibroblasts, endothelial cells, and immune cells such as neutrophils, monocytes/macrophages, and lymphoid cells [7].”
BackgroundGrzeczka, A., Graczyk, S., & Kordowitzki, P. (2025) · GeroScience · doi:10.1007/s11357-025-01520-0 · Cited by 7
“One of its causes is the progressive expansion of ECM components, as well as an energy imbalance, including the loss of crucial proteins, including sirtuins (1–7) [216, 217].”
Mutengo, K. H., Lima, B. B., Mutale, W., Mweemba, A., Kabwe, L., Banda, C., Kaayunga, C., Mulenga, M., Heimburger, D. C., Masenga, S. K., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1534533 · Cited by 7
Song, C., Yang, J., & Gu, Z. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102728 · Cited by 8
Zhao, L., Du, G., Ruze, A., Qi, H.-Z., Zhang, C., Li, Q., Deng, A.-X., Zhao, B.-H., Hu, S., Gai, M., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.05.030 · Cited by 7
Rewiring the scar: translational advances in cardiac fibrosis
Trần, T. N. H., Le, P. H., Yang, S., Luong, T., & Kim, J. (2025) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.25.160 · Cited by 7
Sun, S., Zhang, Z., Li, Y., Zhang, H., Guo, H., Chen, G., Wei, P., Lin, F., & Zhao, G. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1506501 · Cited by 7
Ahmad, W., Dutta, S., He, X., Chen, S., Saleem, M. Z., Wang, Y., & Liang, J. (2025) · Bioengineering · doi:10.3390/bioengineering12090940 · Cited by 7
“These pathologies cause the death of numerous functional cardiomyocytes (CMs) and activate pathological remodeling, resulting in the replacement of contractile myocardium with fibrous tissue [2].”
Sohn, S., Momtahan, N., Stevens, L. M., Han, J., Liu, Y., Kiker, M. T., Recker, E. A., Page, Z. A., & Zoldan, J. (2025) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37997 · Cited by 7
Kif23 Promotes Myocardial Fibrosis by Suppressing Ces1d-Dependent Lipid Metabolism
Chen, H., Xu, J., Huang, Q., Zhao, J., Hu, Y., Wang, C., Zhong, W., Zhang, Y., Fan, C., Chang, J., et al. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25744 · Cited by 7
Transcriptomic dynamics of cardiac remodeling after myocardial infarction
Sanjaya, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-20736-w · Cited by 7
“A separate group of clusters (Clusters 1, 5, 6, 7, and 8) reflected late responses, with expression patterns peaking during the 72-h to 7-day window.”
Epigenetic blockade of SOD2 boosts mitochondria ROS and cytoskeleton remodelling in cardiac fibrosis
Zhang, Y.-S., Liu, Z., Lin, L.-C., Tu, B., Mao, S., Song, K., Liu, P., Yang, J., Chen, Q., Zhao, J., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf257 · Cited by 7
Cardiac magnetic resonance research advances in myocardial fibrosis of hypertrophic cardiomyopathy
Liu, Y., Lv, M., Zhong, J., & Li, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1684960 · Cited by 7
Luo, Y., Yu, Y., Zeng, Z., Chen, Y., Yi, Y., Lu, Z., Zeng, F., Xu, P., Luo, D., Chen, L., et al. (2026) · Advanced Science · doi:10.1002/advs.202519216 · Cited by 7
“However, chronic activation drives excessive fibrosis, characterized by reduced ventricular compliance, impaired diastolic function, inefficient contraction, diminished cardiac output, and disrupted electrical conduction [ 20 ].”
Immunometabolism in Cardiac Remodeling: Mechanisms and Therapeutic Perspectives
Nazaruk, J., Bilnik, B., Niewiadomski, M., Pawlak, W., & Gajewski, P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093906 · Cited by 7
Atrial fibrosis heterogeneity is a risk for atrial fibrillation in pigs with ischaemic heart failure
Zhang, Z., Vlcek, J., Pauly, V., Hesse, N., Bauer, J., Chataut, K. R., Maderspacher, F., Volz, L.-S., Buchberger, K., Xia, R., et al. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14137 · Cited by 7
“11 Thus, we quantified myofibroblasts by counting α -SMA- positive cells 11 in different regions of the heart, both in control and IHF pigs.”
MethodZuo, G., Wang, L., Huang, L., Ren, Y., Ge, Z., Hu, Z., Zhang, J., & Chen, S. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166979 · Cited by 9
An overview of nutritional factors in the aetiopathogenesis of myocardial fibrosis in great apes
Mulders, L. V., Locquet, L., Kaandorp-Huber, C., & Janssens, G. (2024) · Nutrition Research Reviews · doi:10.1017/s0954422424000076 · Cited by 7
Miao, J., Zhang, K., Yang, Y., Xu, S., Du, J., Wu, T., Tao, C., Wang, Y., & Yang, S. (2024) · iScience · doi:10.1016/j.isci.2024.110015 · Cited by 9
Liu, S.-H., Lin, F.-J., Kao, Y., Chen, P., Lin, Y., Lu, Y., Chen, Y., & Chen, Y.-J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147619 · Cited by 7
“Consequently, this process reduces tissue compliance, disrupts electrical conduction, and accelerates the pro-Int gression toward heart failure [39,40].”
BackgroundPentacyclic triterpenes, potential novel therapeutic approaches for cardiovascular diseases
Peng, D., Wang, A. H. J., Shi, W., & Lin, L. (2024) · Archives of Pharmacal Research · doi:10.1007/s12272-024-01510-4 · Cited by 7
“Current therapeutic options for cardiac fibrosis are limited, and research is ongoing to identify new targets and treatments (Frangogiannis 2021).”
Xiao, W., Zhu, Z., Yu, Z., Pan, Y., Xue, Q., Zhou, Y., & Shi, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-71473-5 · Cited by 10
Zhang, L., Yin, H. H., Xie, Y., Zhang, Y., Dong, F., Wu, K., Yang, L., & Lv, H. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13338 · Cited by 7
Byun, J. W., Paeng, J. C., Kim, Y. J., Lee, S., Lee, Y., Choi, H., Kang, K. W., & Cheon, G. J. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267489 · Cited by 7
Scholz, J. A. C., Secreto, F. J., Wobig, J., Kurian, J. R., Hagen, C. E., Zinnen, A. D., Vu, D., Johnson, S. J., Cetta, F., Qureshi, M. Y., et al. (2024) · Cell Transplantation · doi:10.1177/09636897241290367 · Cited by 7
“Cardiac injury activates interstitial myofibroblasts, prompting the secretion and deposition of extracellular matrix proteins, which are critical to wound healing 48 .”
BackgroundMechanistic Relevance of Ventricular Arrhythmias in Heart Failure with Preserved Ejection Fraction
Taqanaki, P. B., Aromolaran, K. A., & Aromolaran, A. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413423 · Cited by 7
Roudi, H. S., Safaei, R., Dabbaghi, M. M., Fadaei, M. S., Saberifar, M., Sakhaee, K., Rahimi, V. B., & Askari, V. R. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128344497241120025757 · Cited by 8
Collagen Pyridinoline Cross-Links Are Absent in Reversible Myocardial Fibrosis
Akam, E. A., Ridley, S. J., Moon, B. F., Caravan, P. D., & Sosnovik, D. E. (2024) · Circulation Research · doi:10.1161/circresaha.124.325406 · Cited by 7
Boeckling, F., Rasper, T., Zanders, L., Pergola, G., Cremer, S., Mas‐Peiró, S., Vasa‐Nicotera, M., Leistner, D. M., Dimmeler, S., & Kattih, B. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037296 · Cited by 7
“27,28 As a measurable gradient of TIMP-1 from coronary sinus to peripheral blood has been demonstrated in cardiac pathology, circulating levels may also account for myocardial fibrosis and support its use as biomarker.”
InfluentialExtracellular matrix in cardiac morphogenesis, fibrosis, and regeneration
Punde, A., Rayrikar, A., Maity, S., & Patra, C. (2025) · Cells and Development · doi:10.1016/j.cdev.2025.204023 · Cited by 8
METTL3 Modulates Radiation‐Induced Cardiac Fibrosis via the Akt/ mTOR Pathway
Qiao, S., Tang, C., Zhu, J., Feng, Y. Y., Li, X., Zhu, J., & Gu, X. (2025) · The FASEB Journal · doi:10.1096/fj.202403143rrrr · Cited by 7
Zhang, W., Zhao, L., Cui, J., Zhang, Y., Li, D., Hong, Z., Liu, J., Wang, S., Zhang, N., Li, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1538046 · Cited by 7
Exploring the Interplay Between Kidney Dysfunction and Cardiovascular Disease
Yadav, R., Abubakar, A. K., Mishra, R., Gupta, S. K., Maurya, N. K., Kashyap, V. K., Rustagi, S., Singh, D. P., & Kumar, S. (2025) · Medical Sciences · doi:10.3390/medsci13020080 · Cited by 11
“Although the scar cannot contract, it is essential for maintaining the structural integrity of the heart chamber [127].”
Saleh, D. O., El-Nasr, N. M. E. A., Elbaset, M. A., Shabana, M. E.-A., Esatbeyoglu, T., Afifi, S. M., & Hashad, I. M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0325767 · Cited by 9
“The accumulation of fat within the myocardium disrupts normal cardiac function, contributing to inflammation, fibrosis, and impaired contractility—key characteristics of DCM [44].”
Li, J., Liu, C., Yang, X., Tian, N., Pan, D., Wang, S., Li, W., & Dai, Z. H. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117822 · Cited by 7
Baba, Y., Maezawa, Y., Kondo, N., Minamizuka, T., Udagawa, H., Ide, S., Ide, K., Teramoto, N., Yamaguchi, A., Kaneko, H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-13102-3 · Cited by 7
“Despite various pathways and transcription factors, including TGFB/SMAD 5 , PDGFB/ERK, WNT/b-CATENIN, and YAP/TAZ, being reported to be involved in the activation of cardiac fibroblasts 6,25–28 , the details of these mechanisms remain unclear.”
Nanomedicine for Diagnosis and Treatment of Cardiac Fibrosis
Montano-Peguero, Y., Verdejo, H., Riquelme, J. A., Kogan, M. J., & Lavandero, S. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s520967 · Cited by 7
“18,21 Cardiac myofibroblasts have a higher proliferative rate, migration capacity, and contractile capacity, and can secrete higher amounts of ECM proteins than CFs. 22,23 The regulation of myocardial collagen turnover is primarily mediated by resident CFs and their differentiation into…”
Wu, S., He, R.-L., Zhao, L., Yu, X., Jiang, Y.-N., Guan, X., Chen, Q.-Y., Ren, F.-F., Xie, Z.-Y., Wu, L., et al. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.10.005 · Cited by 7
The Role of Tβ4-POP-Ac-SDKP Axis in Organ Fibrosis
Wang, W., Jia, W., & Zhang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113282 · Cited by 7
Differential Role of Aldosterone and Transforming Growth Factor Beta-1 in Cardiac Remodeling
Kmieć, P., Rosenkranz, S., Odenthal, M., & Caglayan, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512237 · Cited by 7
Kröpfl, J. M., Beltrami, F. G., Gruber, H., Schmidt‐Trucksäss, A., Dieterle, T., & Spengler, C. M. (2023) · Experimental Physiology · doi:10.1113/ep091277 · Cited by 8
“This is a post hoc analysis of a larger project described elsewhere (Beltrami et al., 2021; Kropfl et al., 2020, 2021).”
MethodZhang, B., Shi, L., Tan, Y., Zhou, Y., Cui, J., Song, Y., Liu, Y., Zhang, M., Duan, W., Jin, Z., et al. (2023) · MedComm · doi:10.1002/mco2.383 · Cited by 8
Metadata
- Authors
- Frangogiannis, N. G.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Frangogiannis, Nikolaos G
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-02
- Volume
- 117
- Issue
- 6
- Pages
- 1450-1488
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- PMC
- PMC8152700
- OpenAlex
- W4210607007
- Cited by
- 1,229
- References
- 615
- Citations by year
- 2026: 265 · 2025: 319 · 2024: 273 · 2023: 210 · 2022: 130 · 2021: 32
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Cardiovascular Research (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH (R01 HL76246, R01 HL85440, R01 HL149407)
- U.S. Department of Defense (PR151134, PR151029, PR181464)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- myocardial fibrosis, myocardial fibroblasts, myofibroblasts, extracellular matrix deposition, TGF-beta, platelet-derived growth factor, cytokines, mechanoreceptors, integrins, pressure overload, myocardial infarction, heart failure, familial cardiomyopathy, diabetic cardiomyopathy, cardiac arrhythmias
- MeSH terms
- Antifibrotic Agents, Animals, Extracellular Matrix, Fibroblasts, Fibrosis, Humans, Cardiomyopathies, Myocytes, Cardiac, Mechanotransduction, Cellular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.